Am J Transplant, Volume 16, Suppl 3 Archives - Page 180 of 180 - ATC Abstracts

2016 American Transplant Congress
Utilization and Discard of HCV+ Donor Livers in the Advent of Direct-Acting Antiviral Therapy.
M. Bowring, L. Kucirka, A. Massie, X. Luo, M. Sulkowski, D. Segev, C. Durand.
JHU, Baltimore.
While 45% of liver candidates are hepatitis C (HCV)-antibody positive (+) and might benefit from a HCV+ donor liver, only a small proportion receive one.…
2016 American Transplant Congress
Insights into the Treatment of Post-Transplant Focal Glomerulosclerosis: Experience Gained from a Concise Diagnostic and Management Protocol.
K. Koutroutsos,¹ R. Charif,¹ L. Moran,² J. Moss,² T. Cook,² C. Roufosse,² D. Taube,¹ M. Loucaidou.¹
¹Kidney and Transplant Centre, Imperial Healthcare NHS Trust, London, United Kingdom; ²Department of Histopathology, Imperial Healthcare NHS Trust, London, United Kingdom.
Background: Recurrence of Focal Glomerulosclerosis (FSGS) after kidney transplantation is associated with poor graft survival. We present results from a concise diagnostic and management protocol…
2016 American Transplant Congress
Donor-Recipient Absolute Weight Mismatch and the Risk of Graft Loss in Renal Transplantation.
A. Miller,¹ B. Kiberd,¹ I. Alwayn,² K. Tennankore.¹
¹Medicine, Division of Nephrology, Dalhousie University, Halifax, NS, Canada; ²Surgery, Multi Organ Transplant Program, Dalhousie University, Halifax, NS, Canada.
Background: Relatively smaller kidney donor to recipient size is proposed to result in increased graft loss due to nephron underdosing and hyperfiltration injury but few…
2016 American Transplant Congress
Composite Score to Define the Risk of Allograft Loss After Standard-of-Care Treatment of Antibody-Mediated Rejection in Kidney Transplantation.
D. Viglietti,¹ A. Loupy,² J. Duong Van Huyen,² J. Verine,¹ A. Zeevi,³ C. Legendre,² D. Glotz,¹ C. Lefaucheur.¹
¹Saint-Louis Hospital, Paris, France; ²Necker Hospital, Paris, France; ³University of Pittsburgh Medical Center, Pittsburgh.
The development of a reliable surrogate endpoint for allograft survival after AMR treatment is a current unmet need in clinical transplantation (FDA AMR Workshop). We…
2016 American Transplant Congress
Pre-Donation Weight Loss Postpones Living Kidney Donation without Attaining the Desired Weight Maintenance in the Midterm.
P. Ventura-Aguiar, E. De Sousa-Amorim, J. Campistol, F. Diekmann, F. Oppenheimer, I. Revuelta.
Renal Transplant Unit, Hospital Clinic, Barcelona, Spain.
Pre-donation weight loss in living kidney donation has two main objectives: reduce surgical risk, and decrease long-term complications from obesity and glomerular hypertrophy secondary to…
2016 American Transplant Congress
MicroRNAs in Urinary Sediments as Non-Invasive Tool to Detect Acute Rejection After Kidney Transplantation.
E. Gielis,^1,2 J. Anholts,² H. de Fijter,³ I. Bajema,⁴ F. Claas,² M. Eikmans.²
¹Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium; ²Immunohematology, LUMC, Leiden, Netherlands; ³Nephrology, LUMC, Leiden, Netherlands; ⁴Pathology, LUMC, Leiden, Netherlands.
MicroRNAs in urine are suitable targets for non-invasive detection of acute rejection (AR), since they represent relatively stable analytes. Indeed, we found that PCR signals…